Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polaprezinc with Abiraterone in Resistant CRPC
NCT05549778Phase 2Completed
- Sponsor
- Jiangnan University
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of polaprezinc in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Jiangnan University. Primary endpoints: Prostate-Specific Antigen Response at 6 months and Radiographic Disease Progression at 6 months. Started Jan 2021; status: completed.
02
Drugs
polaprezinc
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05549778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549778.